BeOne Medicines Earns Buy Rating from JMP Securities

Citizens JMP analyst Reni Benjamin reiterated a Buy rating on BeOne Medicines Ltd. (NASDAQ:ONC) with a price target of $348.00. The company announced positive topline results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma, meeting its primary endpoint of overall response rate and exhibiting clinically meaningful responses. BeOne Medicines Ltd. is a global oncology company that discovers and develops affordable, accessible, and innovative treatments for cancer patients.

Biotech stocks Zai Lab and BeOne Medicines experienced significant declines on Wednesday, September 12, 2025, following reports that President Donald Trump will issue an executive order to reduce U.S. access to drugs developed in China China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order^[1]. The potential move has sparked concerns among investors in the U.S. biotech space and companies like Pfizer and AstraZeneca, which have been sourcing low-priced drugs from China.

According to the New York Times, the draft order calls for boosting U.S. production of certain medicines and giving preference to American-made products in government purchases China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order^[1]. This could lead to a shift in the biotech landscape, potentially benefiting U.S.-based companies but also creating new challenges.

Zai Lab, headquartered in Shanghai, saw its shares tumble 9% to 28.65, while BeOne Medicines, which originated out of China as BeiGene, dropped 10.5% to 314.23 China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order^[1]. The declines highlight the sensitivity of the biotech sector to geopolitical risks and regulatory changes.

Leerink Partners analyst David Risinger does not expect the move to bolster U.S.-based biotech stocks. Instead, he believes U.S. biopharma would be better served by "positive U.S. government actions," such as lower regulatory burdens and financial incentives China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order^[1]. However, restrictions on U.S. biopharma companies licensing or acquiring assets out of China could backfire, potentially leading to foreign companies capitalizing on the void and commercializing novel drugs in the U.S. and globally.

In a separate development, BeOne Medicines Ltd. (NASDAQ:ONC) announced positive topline results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma, meeting its primary endpoint of overall response rate and exhibiting clinically meaningful responses BeOne Medicines (ONC) Reports Positive Phase 1/2 Results ...^[2]. The company plans to send the data for possible approval to the U.S. Food and Drug Administration and other international regulatory agencies.

Citizens JMP analyst Reni Benjamin reiterated a Buy rating on BeOne Medicines Ltd. (NASDAQ:ONC) with a price target of $348.00, citing the positive results for Sonrotoclax BeOne Medicines (ONC) Reports Positive Phase 1/2 Results ...^[2].